Professor Jérôme Frenette is a researcher with a background in physical therapy and post-graduate training in muscle physiology and immunology at the University of California in Los-Angeles. He is a full-time researcher at the Centre de recherche du CHU de Québec-Laval University, and full professor in the department of rehabilitation at Laval University’s School of Medicine. He has been the principal investigator on several CIHR and NSERC grants. Many of his publications, and one CIHR grant were recognized and rewarded as being among the best in the field of muscle physiology. He started his career as a researcher by investigating the roles played by blood cells and mechanical loading in models of tendon injury and muscle atrophy/regrowth. In 2005, he expanded his research program to include the Buruli Ulcer, which is caused by mycobacterium ulcerans, a neglected disease of wet tropical zones, that is closely related to tuberculosis and leprosy. His research group was the first to show that mycobacterium ulcerans and its toxin, mycolactone, extend well beyond the skin, and severely affect underlying skeletal muscles. Today, the focus of his research program is to understand the link between osteoporosis and muscle atrophy/disease through one common pathway i.e. the RANK/RANKL/OPG pathway. In collaboration with Duchenne muscular dystrophy foundations in Canada, the United States and Australia, as well as sustainable financial support from public and private sources, his team is developing new drugs that would potentially alleviate, in tandem, osteoporosis and muscle degeneration in Duchenne muscular dystrophy patients or other forms of bone and muscle diseases.

CHUL
2705, boulevard Laurier
P-09823
Québec, Québec
Canada G1V 4G2
+1 418-525-4444, extension 47779
+1 418-654-2145
jerome.frenette@crchudequ...

Latest news

67 entries « ‹ 1 of 7 › »

Pryce BR, Labreche C, Hamoudi D, Abou-Hamad J, Al-Zahrani KN, Hodgins JJ, Boulanger-Piette A, Bosse S, Balog-Alvarez C, Frenette J, Ardolino M, Kornegay JN, Sabourin LA

Muscle-specific deletion of SLK/Stk2 enhances p38 activity and myogenesis in mdx mice.

Journal Article

Biochim Biophys Acta Mol Cell Res, 1868 (2), 2021.

Abstract | Links:

Beauchamp F, Boucher V, Neveu X, Ouellet V, Archambault P, Berthelot S, Chauny JM, de Guise E, Émond M, Frenette J, Lang E, Lee J, Mercier É, Moore L, Ouellet MC, Perry J, Le Sage N

Post-concussion symptoms in sports-related mild traumatic brain injury compared to non-sports-related mild traumatic brain injury.

Journal Article

CJEM, 23 (2), 2021.

Abstract | Links:

Blais Lécuyer J, Mercier É, Tardif PA, Archambault PM, Chauny JM, Frenette J, Perry J, Stiell I, Émond M, Lee J, Lang E, Boucher V, Berthelot S, McRae A, Le Sage N

S100B protein level for the detection of clinically significant intracranial haemorrhage in patients with mild traumatic brain injury: a subanalysis of a prospective cohort study.

Journal Article

Emerg Med J, 38 (4), 2021.

Abstract | Links:

Hamoudi D, Bouredji Z, Marcadet L, Yagita H, Landry LB, Argaw A, Frenette J

Muscle weakness and selective muscle atrophy in osteoprotegerin-deficient mice.

Journal Article

Hum Mol Genet, 29 (3), 2020.

Abstract | Links:

Le Sage N, Tardif PA, Frenette J, Emond M, Chauny JM, Moore L, Archambault P, Perry J, Boulanger-Piette A

Detection of S-100β Protein in Plasma and Urine After a Mild Traumatic Brain Injury.

Journal Article

Can J Neurol Sci, 46 (5), 2019.

Abstract | Links:

Hamoudi D, Marcadet L, Yagita H, Bouredji Z, Argaw A, Frenette J, Piette Boulanger A

An anti-RANKL treatment reduces muscle inflammation and dysfunction and strengthens bone in dystrophic mice.

Journal Article

Hum Mol Genet, 28 (18), 2019.

Abstract | Links:

Dufresne SS, Boulanger-Piette A, Bosse S, Argaw A, Hamoudi D, Marcadet L, Gamu D, Fajardo VA, Yagita H, Penninger JM, Russell Tupling A, Frenette J

Genetic deletion of muscle RANK or selective inhibition of RANKL is not as effective as full-length OPG-fc in mitigating muscular dystrophy.

Journal Article

Acta Neuropathol Commun, 6 (1), 2018.

Abstract | Links:

Boulanger Piette A, Hamoudi D, Marcadet L, Morin F, Argaw A, Ward L, Frenette J

Targeting the Muscle-Bone Unit: Filling Two Needs with One Deed in the Treatment of Duchenne Muscular Dystrophy.

Journal Article

Curr Osteoporos Rep, 16 (5), 2018.

Abstract | Links:

Boulanger Piette A, Hamoudi D, Marcadet L, Kyomi Labelle F, Ovidiu David R, Bosse S, Argaw A, Frenette J

Utrophin haploinsufficiency does not worsen the functional performance, resistance to eccentric contractions and force production of dystrophic mice.

Journal Article

PLoS One, 13 (6), 2018.

Abstract | Links:

Dionne CE, Laurin D, Desrosiers T, Abdous B, Le Sage N, Frenette J, Mondor M, Pelletier S

Vitamin C is not the Missing Link Between Cigarette Smoking and Spinal Pain.

Journal Article

Spine (Phila Pa 1976), 43 (12), 2018.

Abstract | Links:

67 entries « ‹ 1 of 7 › »
Signaler des ajouts ou des modifications

Active projects

  • Deciphering the role of RANK/RANKL/OPG in skeletal muscle., from 2016-04-01 to 2022-03-31
  • Development of a monosaccharide therapy using N-acetylglucosamine to mitigate Duchenne muscular dystrophy, from 2021-05-31 to 2024-05-30
  • Does anti-RANKL therapy prevent glucocorticoid induced bone loss and promote muscle function in a mouse model of Duchenne muscular dystrophy, from 2021-04-01 to 2022-03-31
  • Investigation of the role of galectin-3 and its ligands in skeletal muscle strength, regeneration, and pathology, from 2018-10-01 to 2023-03-31
  • La protéine S100B est-elle un outil de dépistage valide pour réduire le nombre de tomodensitométries inutiles suite à un traumatisme cranio-cérébral léger?, from 2017-04-01 to 2022-01-31
  • Multifunctional properties of osteoprotegerin in muscular dystrophy and muscle repair, from 2020-04-01 to 2025-03-31

Recently finished projects

  • Development of a therapy for Duchenne muscular dystrophy using N-acetylglucosamine, from 2019-06-15 to 2021-03-31
  • Does anti-RANKL therapy prevent glucocorticoid induced bone loss in a mouse model of Duchenne muscular dystrophy?, from 2020-10-01 to 2021-07-31
  • Therapeutic impact of OPG on muscle structure and function in a preclinical mouse model of Duchenne Muscular Distrophy, from 2016-02-17 to 2021-02-16
  • To understand mechanistically how RANK/RANKL/OPG and b-adrenergic pathways mitigate Duchenne muscular dystrophy, from 2016-07-01 to 2020-06-30
Data provided by the Université Laval research projects registery